Related Experiment Video
Updated: Apr 12, 2026
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid
Marvin M van Luijn1, Willemijn van den Ancker2, S Marieke van Ham3
1Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center ; Amsterdam, The Netherlands ; Department of Immunology; Erasmus MC University Medical Center ; Rotterdam, The Netherlands.
Abstract:
The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.
Insights
Minimal residual disease (MRD) in acute myeloid leukemia (AML) leads to relapse. Class II-associated invariant chain peptide (CLIP) expression on residual AML cells indicates a poor prognosis, highlighting a new target for therapy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) patients often achieve remission with chemotherapy but frequently relapse.
- Minimal residual disease (MRD) is a key factor predicting relapse in AML survivors.
- Identifying markers of MRD is crucial for improving AML patient outcomes.
Purpose of the Study:
- To investigate the prognostic significance of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells in AML patients.
- To explore CLIP as a potential biomarker for minimal residual disease (MRD) in AML.
Main Methods:
- Analysis of residual leukemic cells from AML patients in remission.
- Assessment of class II-associated invariant chain peptide (CLIP) expression levels on these cells.
- Correlation of CLIP expression with patient relapse rates and overall survival.
Main Results:
- Elevated expression of class II-associated invariant chain peptide (CLIP) was observed on residual leukemic cells.
- Higher CLIP expression levels were significantly associated with a higher likelihood of relapse.
- CLIP expression on residual AML cells serves as a poor prognostic indicator.
Conclusions:
- Class II-associated invariant chain peptide (CLIP) expression is a significant negative prognostic factor in AML.
- CLIP may serve as a valuable biomarker for minimal residual disease (MRD) detection.
- Targeting CLIP expression on residual leukemic cells could offer novel therapeutic strategies for AML.
